4 results about "Blood count" patented technology

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

The embodiment of the invention provides a construction method of a thalassemia screening model, equipment, a medium and a program product, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring a whole blood cell counting parameter and a classification label of a training set sample; the training set samples are divided into minority class samples and majority class samples according to the types of the classification labels; calculating k neighbors of each minority class sample, and dividing the minority class samples into dangerous samples and non-dangerous samples according to the proportion of majority class samples in the neighbors; selecting any sample from m nearest minority-class neighbors of each dangerous sample as a neighbor sample to be tested, and generating a new sample on a connecting line of the single dangerous sample and the neighbor sample to be tested through linear interpolation; and training the parameters of the new samples, the majority samples and the non-dangerous samples to obtain a screening model. According to the application, a robust multi-class screening model is established by using conventional whole blood cell count data so as to accurately distinguish key thalassemia genotypes.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

The embodiment of the invention discloses a valuing method for simulating cell viability measurement by adopting a fluorescent label counting standard substance, and relates to the technical field of biological detection. The method comprises the following steps: preparing a fluorescent microsphere suspension; pretreating the suspension liquid; dropwise adding the suspension into a counting chamber of a blood counting plate; respectively counting in a bright field environment and a dark field environment of the microscope; calculating the luminous efficiency of the microspheres and the cell viability according to the counting result of the microscope; measuring for multiple times, and taking an average value as a constant value result; analyzing and calculating the uncertainty of the standard substance; and verifying the constant value method. The valuing method provided by the invention has good accuracy, reliability and quantity traceability, and further provides a reliable basis for quantitative analysis of the cell viability.